Prostate Cancer NEWS You Can Use  
 
Us TOO news e-messages
 Us TOO Prostate Cancer NEWS You Can Use

Cancer Network Highlights the Top Stories From the 2014 ASCO Annual Meeting
NORWALK, Conn., June 17, 2014 /PRNewswire/ -- UBM Medica US announces that Cancer Network, a leading online community for oncologists, presents exclusive coverage of the American Society of Clinical Oncology (ASCO) Annual Meeting, held May 30-June 3 in Chicago. This year, the ASCO Annual Meeting brought together more than 30,000 oncology professionals from a broad range of specialties to share ...

Studies from Department of Surgery in the Area of Prostate Cancer Reported (Incidence of Groin Hernia Repair After Radical Prostatectomy A...
Studies from Department of Surgery in the Area of Prostate Cancer Reported (Incidence of Groin Hernia Repair After Radical Prostatectomy A Population-Based Nationwide Study) By a News Reporter-Staff News Editor at Biotech Week -- A new study on Oncology is now available. According to news reporting originating from Ostersund, Sweden, by NewsRx correspondents, research stated, "To assess the ...

NCI -Vasectomy may increase risk of aggressive prostate cancer
ENP Newswire - 11 July 2014 Release date- 10072014 - Boston, MA-Vasectomy was associated with a small increased risk of prostate cancer, and a stronger risk for advanced or lethal prostate cancer according to a new study from Harvard School of Public Health (HSPH). The researchers found that the association remained even among men who received regular PSA screening, suggesting the increased ...

Astellas Details Pipeline Progress at R&D Meeting
TOKYO, July 11, 2014 /PRNewswire/ -- Astellas today announced progress on the Company's efforts to reshape its research framework at its R&D meeting held in Tokyo on July 10. The meeting provided an opportunity for Astellas to present a comprehensive overview of its late-stage clinical programs and corporate strategy. The purpose of the meeting was to provide an update on the initiatives for ...

Secretary Paige Asks President to Light White House Blue for Prostate Cancer
Houston, TX (PRWEB) June 17, 2014 The Honorable Dr. Rod Paige, United States Secretary of Education (2001-2005), joins the growing list of high-profile supporters for the movement to light the White House blue for an evening during September's Prostate Cancer Awareness Month. On why the movement resonated with him, Dr. Paige says, "I am a survivor of prostate cancer, the second leading cancer ...

Living with a Disability Magazine Marks National Men's Health Awareness Month with Article on How Prostate Cancer can Be a Disabling Condition
San Antonio. TX (PRWEB) June 25, 2014 To mark National Men's Health Awareness Month, which occurs every June, the Editorial Board of Living with a Disability magazine has published an important new article on how prostate cancer can become a disabling condition. As the article highlights, prostate cancer is considered a disability by the Social Security Administration for those afflicted with ...

AdMeTech Foundation: Massachusetts Legislators Approve Key Funding for Prostate Cancer Awareness Campaign
BOSTON, July 1, 2014 /PRNewswire-USNewswire/ -- The Massachusetts' House of Representatives and Senate today placed the state in a national leadership position by creating a new education and awareness program dedicated to prostate cancer. The $500,000 campaign, contained in the conference committee report of the FY15 budget, is aimed at saving lives, improving quality of life, and reducing ...

Guidelines Address Long-Term Needs of Prostate Cancer Survivors
ATLANTA, June 10 -- The American Cancer Society has issued the following news release: New American Cancer Society Prostate Cancer Survivorship Care guidelines released today outline posttreatment clinical follow-up care for the myriad of long-term and late effects an estimated 2.8 million prostate cancer survivors in the United States may face. The guidelines report is published Early Online ...

Prostate Cancer Detection: The Role of Primary Care Physicians
NEW YORK, NY -- (Marketwired) -- 05/15/14 -- A recent European prostate cancer screening survey yielded surprising results to those leading the prostate cancer battle. Approximately 1,000 non-urologic specialists were asked about their prostate cancer screening practices and use of the prostate-specific antigen (PSA) test for patients aged 50 or older. In response to an in-person ...

Prostate Cancer Canada advocates for fair and equal access to prostate cancer testing
Ontario is one of only two provinces that don't cover PSA tests TORONTO, May 23, 2014 /CNW/ - Prostate Cancer Canada has launched a new campaign urging the Ontario government to cover the cost of PSA screening tests for prostate cancer. One in 7 Canadian men will be diagnosed with prostate cancer in their lifetime. If prostate cancer is detected early through a simple and affordable PSA test, ...

Traditional Asian remedy found to fight prostate cancer
A widely used traditional Asian health food supplement can actually help to inhibit the growth of prostate cancer cells, depending on its production process, according to New Zealand research released on Thursday. University of Auckland researcher Ben Kao compared the impact of different ethanol and water-based extracts of the Ganoderma lucidium genus of mushrooms on cell lines of prostate ...

Dendreon Announces Leadership Transition
John H. Johnson to Step Down as Chairman, President and CEO; Douglas G. Watson Elected Chairman SEATTLE--(BUSINESS WIRE)-- Dendreon Corporation (Nasdaq:DNDN) today announced that John H. Johnson has informed the Board of Directors of his plans to step down as president and chief executive officer for personal reasons. Mr. Johnson has resigned from the Board, effective June 3, 2014, and the ...

Japan : Astellas Announces Launch of XTANDI (enzalutamide) Capsules in Japan for Prostate Cancer Treatment
Astellas Pharma Inc. announced that oral androgen receptor signaling inhibitor, XTANDI Capsules 40mg (generic name: enzalutamide) becomes available for the treatment of patients with castration-resistant prostate cancer in Japan today. XTANDI is an oral, once-daily, androgen receptor signaling inhibitor. It inhibits multiple steps in the androgen receptor signaling pathway, which has been ...

Takeda: Orteronel Plus Prednisone Improves Progression Free Survival in Men with Chemotherapy-Naive Metastatic Castration Resistant Prostate Cancer
Takeda Pharmaceutical Company Limited announced data from ELM- PC4, a pivotal, international, double blind, randomized Phase 3 trial showing that the investigational drug orteronel plus prednisone reduced the risk of radiographic progression free survival (rPFS), one of the study's two primary endpoints, by 30 percent compared to placebo plus prednisone in men with chemotherapy- naive ...

Identified 2 new genes involved in the more aggressive prostate cancer
By a News Reporter-Staff News Editor at Cancer Weekly -- Prostate cancer Prostate cancer is the most common in men in Europe( accounts for 20% of all male tumors). The incidence is about 60 new cases per 100,000 inhabitants per year. A tumor closely associated with old age, and most cases is diagnosed between 70 and 80 years. The progressive aging of the population has made it one of the ...

MDxHealth Announces Presentations on ConfirmMDx for Prostate Cancer at American Urological Association 2014 Annual Meeting
IRVINE, Calif., and HERSTAL, BELGIUM, May 15, 2014 (GLOBE NEWSWIRE) -- MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced that results from its pivotal clinical validation study for ConfirmMDx® for Prostate Cancer will be highlighted in two oral ...

TOLMAR Pharmaceuticals Established To Market ELIGARD For Advanced Prostate Cancer In The U.S. And Puerto Rico
LINCOLNSHIRE, Ill., May 16, 2014 /PRNewswire/ -- TOLMAR Pharmaceuticals, Inc., focused on specialty pharmaceutical products, today announced that, effective May 8, 2014, the company holds exclusive distribution rights to ELIGARD® (leuprolide acetate for injectable suspension) in the U.S. and Puerto Rico. ELIGARD is a prescription medication for the palliative treatment (management of symptoms) ...

Study shows image fusion-guided biopsy improves accuracy of prostate cancer diagnosis
By a News Reporter-Staff News Editor at Clinical Trials Week -- NEW HYDE PARK, NY - A recent study by investigators from LIJ Medical Center demonstrated that using magnetic resonance imaging (MRI) in men with an elevated prostate specific antigen (PSA) resulted in a prostate cancer detection rate that was twice as high as data reported in the March 1999 Prostate journal that analyzed men ...

ImaginAb reports initial Phase I/IIa results of prostate imaging agent
US-based ImaginAb in collaboration with Memorial Sloan-Kettering Cancer Center (MKSCC) has reported initial Phase I/IIa results of 89Zr-Df-IAB2M, an anti-PSMA recombinant antibody fragment (a minibody) derived from the huJ591 monoclonal antibody, in patients with metastatic prostate cancer. The presentation of the initial data at Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual ...

Tokai Pharmaceuticals Reports Clinical Data for Galeterone in Patients with Advanced Prostate Cancer
Tokai Pharmaceuticals reported positive interim results from the Phase 2 ARMOR2 study of galeterone (TOK-001) among patients with castration-resistant prostate cancer (CRPC). Tokai Pharmaceuticals said in a release that these data demonstrated clinically meaningful reductions in prostate-specific androgen (PSA) levels, a marker of prostate cancer growth. The company reported that the data were ...

Data on Prostate Cancer Reported by Researchers at Duke University
By a News Reporter-Staff News Editor at Biotech Week -- Research findings on Oncology are discussed in a new report. According to news reporting from Durham, North Carolina, by NewsRx journalists, research stated, "Radiotherapy is an effective tool for the palliation of symptoms commonly caused by prostate cancer. The majority of painful bone metastases respond equally well to, single or ...

Investigators from Institute of Cancer Research Release New Data on Prostate Cancer
By a News Reporter-Staff News Editor at Cancer Weekly -- Investigators publish new report on Oncology. According to news reporting from Surrey, United Kingdom, by NewsRx journalists, research stated, "The diagnosis of prostate cancer (PC) can provide a trigger for dietary change, and there is evidence that healthier diets may improve quality of life and clinical outcomes. However, men's views ...

Low risk prostate cancer not always low risk
By a News Reporter-Staff News Editor at Biotech Week -- However, according to a new UCLA study, selection of men for active surveillance should be based not on the widely used conventional biopsy, but with a new, image-guided targeted prostate biopsy. The new biopsy method, pioneered by a multi-disciplinary team on the Westwood campus, is now a routine part of the UCLA active surveillance ...

Major advances in breast, prostate, colorectal cancer featured at ASCO Annual Meeting
By a News Reporter-Staff News Editor at Biotech Week -- CHICAGO - Findings from four phase III clinical trials in breast, prostate, and colorectal cancers were released at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO). The studies were presented in ASCO's Plenary session, which features the meeting's most important clinical cancer research with the greatest ...

Treatment extends life for men with prostate cancer
A new treatment has been shown to extend the lifespans of men with advanced prostate cancer by as much as one year, researchers said. The study involved 790 men who were diagnosed with metastatic prostate cancer, meaning the disease had spread beyond the prostate, according to New York Times. By adding the chemotherapy drug docetaxel to standard hormone therapy, known as androgen deprivation ...

Prostate Cancer Drug Delivers Benefits Before Chemotherapy
PORTLAND, Ore., June 2 -- Oregon Health & Science University issued the following news release: Results of international clinical trial, led by Knight Cancer Institute at Oregon Health & Science University and published in the New England Journal of Medicine, showed use of enzalutamide before chemotherapy cut risk of disease progression by 81% A drug used to treat men with late-stage prostate ...

J&J -IMAAGEN Data Demonstrate that Abiraterone Acetate Plus Prednisone (5mg once daily) Lowers PSA Levels in Men with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer (M0-CRPC)
ENP Newswire - 03 June 2014 Release date- 02062014 - HORSHAM, PA, - Abiraterone acetate (ZYTIGA) plus prednisone demonstrated statistically significant reductions in PSA levels at six months, the primary endpoint of the IMAAGEN trial, which evaluates the investigational use of abiraterone acetate plus prednisone (5 mg once daily) in patients with non-metastatic castration-resistant prostate ...

Germany : BAYER, ORION amalgamates on dealing and advancing Prostate Cancer Drug
Bayer and Orion recently declared that they have engaged into a global partnership. This partnership is meant to raise as well as commercialize the investigation compound ODM-201 for the treatment of patients with prostate cancer. As per the terms of the contract, together, firms will develop ODM-201. In addition, the Orion has an alternative to co-promote the drug in Europe and on product ...

Gene Therapy Combined with IMRT Found to Reduce the Rate of Positive Prostate Biopsy After Treatment for Intermediate-Risk Prostate Cancer Patients
FAIRFAX, Va., June 2 -- The American Society for Radiation Oncology issued the following news release: Combining oncolytic adenovirus-mediated cytotoxic gene therapy (OAMCGT) with intensity modulated radiation therapy (IMRT) reduces the risk of having a positive prostate biopsy two years after treatment in intermediate-risk prostate cancer without affecting patients' quality of life, according ...

Karyopharm Announces Initiation of Phase 2 Study of Selinexor (KPT-330) in Patients with Hormone Refractory Prostate Cancer (SHIP Study)
NATICK, Mass., June 9, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases, today announced the initiation of a Phase 2 trial of its novel, oral Selective Inhibitor of ...

Survey Shows Less Than Half of Men With Prostate Cancer Are Referred to an Oncologist
WASHINGTON, June 12, 2014 /PRNewswire-USNewswire/ -- A new prostate cancer survey revealed that only 41 percent of men with prostate cancer were referred to an oncologist at some point during their prostate cancer journey. The survey, released by ZERO – The End of Prostate Cancer, is the organization's first patient education survey, with the goal of better understanding the experiences of ...

Light The White House Blue Campaign Launches For Prostate Cancer Awareness Month
By a News Reporter-Staff News Editor at Politics & Government Week -- The Blue Cure Foundation announces the launch of a nationwide campaign petitioning the President to light the White House blue for one night in recognition of September's Prostate Cancer Awareness Month. To heighten awareness of cancer prevention and healthy lifestyle choices, Blue Cure plans to collect 100,000 signatures on ...

Astellas and Medivation Receive Priority Review from FDA for XTANDI® (Enzalutamide) Capsules In Chemotherapy-Naive Advanced Prostate Cancer
TOKYO and SAN FRANCISCO, May 6, 2014 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503) and Medivation Inc. (NASDAQ: MDVN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the supplemental New Drug Application (sNDA) to extend the indication for XTANDI® (enzalutamide) capsules for the treatment of men with metastatic castration-resistant prostate cancer ...

Teva and OncoGenex Announce Top-Line Survival Results of Phase III SYNERGY Trial Evaluating Custirsen in Combination with First-line Docetaxel and...
Teva and OncoGenex Announce Top-Line Survival Results of Phase III SYNERGY Trial Evaluating Custirsen in Combination with First-line Docetaxel and Prednisone for Metastatic Castrate-Resistant Prostate Cancer By a News Reporter-Staff News Editor at Cancer Weekly -- Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) and OncoGenex Pharmaceuticals, Inc. (NASDAQ:OGXI) announced results from the Phase ...

Genomic Health Announces Presentation of Multiple Oncotype DX® Studies in Breast, Prostate, Colon and Renal Cancers at the American Society of Clinical Oncology (ASCO) Annual Meeting
REDWOOD CITY, Calif., May 5, 2014 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that results from nine studies of Oncotype DX® in breast, colon, prostate and renal cancer will be presented at the American Society of Clinical Oncology® (ASCO®) Annual Meeting, taking place May 30 - June 3, 2014 at McCormick Place in Chicago. New data, including two oral presentations, ...

Nymox Reports New Prostate Cancer Clinical Trial Results
Nymox Pharmaceutical Corporation (Nasdaq: NYMX) announced today new positive outcome results from the Company's ongoing prospective trial of NX-1207 for the treatment of low grade localized prostate cancer. These are the first clinical patient treatment outcome results for this trial. A controlled comparison was conducted of patients who required and received radiation and surgery treatments ...

IsoRay's Cancer Fighting Cesium-131 Isotope in Published Report Shows Significant Results in Early Clinical Interstitial Implants for Gynecologic Malignancies
IsoRayInc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications, today announced the publication of the first major peer reviewed study showing improved results usingIsoRay'sCesium-131 seeds in the treatment of gynecologic cancer.IsoRayCEO Dwight Babcock commented, "We are very excited to have our Cesium-131 isotope seeds ...

Prostate Cancer: Watch and Wait or Ignore and Wait?
By a News Reporter-Staff News Editor at Cancer Weekly -- A long-term European study highlighted key patient compliance issues in the prostate cancer active surveillance strategy. In lieu of proactive prostate cancer treatments such as robotic prostate surgery, hormone therapy, or radiation, some men choose to postpone treatment and monitor the progression of their disease. Researchers found ...

BPH Patients Are Not Safe Taking Testosterone, While Dr. Allen's Device Terminates Prostate Enlargement and Increases Energy Naturally, States Fine Treatment
London, GB (PRWEB) May 03, 2014 Fine Treatment recommends that a man with benign prostatic hyperplasia (BPH) should use Dr. Allen's Device in the first place, as it diminishes the enlarged prostate size naturally relieving lower urinary tract symptoms and increasing male energy. At the same time, commonly used to boost a man's energy testosterone, according to the article in the WWL-News, it ...

Vitamin D: A Sunny Outlook for Prostate Cancer
NEW YORK, NY -- (Marketwired) -- 05/08/14 -- Vitamin D deficiency could be a predictor for aggressive prostate cancer, according to a study funded by The National Institutes of Health and the U.S. Department of Defense. In examining the prostate biopsy results of men with abnormal prostate-specific antigen (PSA) levels and/or digital rectal exams (DREs), researchers discovered that men with ...

New model can predict therapy outcomes in prostate cancer with bone metastasis
By a News Reporter-Staff News Editor at Cancer Weekly -- PHILADELPHIA - A new computational model that simulates bone metastasis of prostate cancer has the potential to rapidly assess experimental therapy outcomes and help develop personalized medicine for patients with this disease, according to data published in Cancer Research, a journal of the American Association for Cancer Research (see ...

Memorial Sloan-Kettering's Dr. Howard Scher Reaffirms Commitment to Lead Phase I Trials for AV Therapeutics' Prostate Cancer Drug
NEW YORK, May 7, 2014 (GLOBE NEWSWIRE) -- AV Therapeutics, Inc. ("AV Therapeutics" or the "Company") (OTCQB:AVTH), a developer of cancer therapeutics and vaccines, announced Howard Scher, MD, Chief, Genitourinary Oncology Service and D. Wayne Calloway Chair in Urologic Oncology at Memorial Sloan-Kettering Cancer Center, reaffirmed his commitment to lead AV Therapeutics' Phase I clinical trial ...

Prostate Cancer Foundation Receives over $8.4M Movember Donation
SANTA MONICA, Calif.--(BUSINESS WIRE)-- The Prostate Cancer Foundation (PCF) has received over $8.4 million from its partner Movember, the global men’s health charity that gets men to grow and women to support the moustache for the month of November, raising vital funds and awareness for men’s health. PCF will allocate the over $8.4 million to find better treatments and ultimately a cure, by ...

 
 

Facebook - UsToo.org  Twitter - UsToo.org  LinkedIn - UsToo.org Inspire prostate cancer discussions – UsToo.org 

Contact Us | Privacy Policy | Terms & Conditions | Disclaimer   

 
Copyright © 2005-2014 Us TOO International, Inc.
Designed and hosted by ACCESS Medical Group, Ltd.